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ABSTRACT
In 2001, ISPOR convened a Task Force on Code of Ethics
for Researchers (The Task Force). This Task Force was to
build on the previous work of ISPOR Health Science Pol-
icy Task Forces and develop a code of ethics that would be
applicable to all ISPOR members and to ISPOR itself. The
Task Force developed a code of ethics that was subse-
quently adopted by the ISPOR Board of Directors. The
Code of Ethics is appended to this article and can be
found on ISPOR’s Web page at http://www.ispor.org/
workpaper/code_ethic.htm. This article provides support-
ive information and justiﬁcation for the ISPOR Code of
Ethics for Researchers and includes a discussion of the
stakeholders as well as ethical considerations for the
researcher on research practices, research sponsorship,
research publication and dissemination, and relationships
with others. It also includes a discussion of the ethical
considerations for the Society.
Keywords: ethics, publication, research, researchers,
sponsorship.
Introduction
As an overriding precept, it would be prudent to say
that an ISPOR researcher’s ﬁrst relationship is to
assist patients, physicians, and payers to attain the
greatest value, both therapeutic and economic, from
medical therapies. ISPOR is an organization that
represents research professionals from a variety of
disciplines. These include but are certainly not lim-
ited to economists, epidemiologists, social and
behavioral scientists, health services researchers,
researchers in managed care organizations, physi-
cians, pharmacists, and many others. As an organ-
ization, ISPOR expects itself and its members to
adhere to the highest ethical standards. In attempt-
ing to meet these expectations, ISPOR recognizes
that its activities and those of its members affect a
number of constituencies and these are included in
the following paragraphs.
Patients
It should be generally agreed that patients are ulti-
mately going to experience the greatest impact of
the research conducted by ISPOR members. As the
results of the research are digested by others and
incorporated into their programs of pharmacy and
medicine, the decisions that are made are going to
impact patients most. For example, will patients be
denied coverage for certain drugs? Will they be
forced into additional cost sharing for a particular
drug? Will they be shifted from one drug to the next
while they are attempting to control a chronic con-
dition? And will they receive the most appropriate
therapy for their conditions at the most reasonable
price?
Payers, Decision Makers, and Administrators
Although the patients are certainly the ultimate
focus of medical care, being able to provide com-
prehensive care to patients for an affordable cost is
a challenge. Deciding what would be covered and
the extent of that coverage while attempting to
ensure that the health of the patient is not compro-
mised requires credible information. The individuals
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who must make decisions about coverage and cost
require results of studies that are both practical and
useful, reﬂecting the fact that the information pre-
sented must be in such a form that individuals who
may not be trained in research can understand and
apply the information.
Practitioners
Physicians, pharmacists, and others will be treating
patients with interventions made available because
of particular research. The research presented to the
various practitioners must meet the relevant stand-
ards of practice for research so that the practitioners
have available to them the best tools to help their
patients.
Government Groups
Governments still represent the largest payers of
health care, and their need for reliable research
based information is signiﬁcant. The policies and
practices adopted for government programs tend to
establish standards that others follow. For example,
although rebates are taken for granted as a normal
aspect of doing business today, they did not emerge
as a major cost containment tool until around 1990.
The Profession of  Outcomes Researchers
This is a rather broad-based profession in that out-
comes researchers represent a variety of research
disciplines that include but are not limited to epide-
miologists, economists, health services researchers,
clinical scientists, and others. Each of these repre-
sents a research profession in and of itself, and each
essentially has its own standards, practices and con-
ventions. An economist and an epidemiologist may
approach the same issue from two slightly different
perspectives. For example, an economist may
develop a behavioral model that requires parameter
estimates from a variety of sources, whereas an epi-
demiologist may make greater use of statistical
analyses of large databases.
Colleagues, Research Employees, and Students Who 
Work for Researchers
In dealing with colleagues one must be cognizant of
the professional relationships and the rights and
responsibilities of colleagues when conducting col-
laborative research. Colleagues are generally inde-
pendent researchers with their own reputations.
Research employees are also colleagues in the sense
that they are often doctorally trained individuals
with their own careers. They must be accorded
respect and given appropriate credit for the work
they perform on research projects.
Employers
Under the current system of medical care, employ-
ers are responsible for providing a substantial
amount of health-care coverage to employees and
their dependents as well as retirees. Employers are
pressured to provide reasonable health-care cover-
age at an affordable cost. Given that the cost of
medical care increases substantially every year this
becomes more and more of a challenge. Notwith-
standing other medical care items, expenditures for
prescription drugs are increasing at approximately
15% per year and so employers are challenged
to provide a comprehensive drug beneﬁt while
attempting to minimize employee out-of-pocket
costs. Therefore, the research that is conducted by
ISPOR members and their colleagues can directly
affect price and coverage negotiations and the
employers’ decision as to which beneﬁts to provide.
Clients
Researchers develop relationships with clients over
time and the researcher–client relationship is vital
to the continuation of the researchers’ business
whether private or nonproﬁt. In pursuing research
and maintaining this relationship, it is important
that both parties understand and accept ethical
principles surrounding that relationship.
Design and Research Practices
ISPOR members must maintain a current knowl-
edge of research practices. In dealing with relation-
ships among any of the constituencies, especially
clients, payers, and decision makers, members have
an ethical obligation to remain current in the ﬁeld.
In addition, members should adhere to standards of
outcomes research practice for their respective ﬁelds
as well as identify any ofﬁcial guidelines or stand-
ards that they may have used. For examples of
research standards that could be considered by
members, Value in Health has been publishing the
ISPOR Scientiﬁc Task Force reports in 2003.
Members’ research designs should be deﬁned a
priori, reported transparently, defended relative to
alternatives, and planned to minimize all types of
bias [1–4]. Transparency is absolutely critical. At no
time should a reader or user of the research be
expected to act on ﬁndings where there may be
questions as to how the research was conducted or
the data interpreted. Journals must be encouraged
to allow sufﬁcient space to publish detailed infor-
mation on the research designs [5,6]. For rand-
omized controlled trials (RCTs), the Consolidated
Standards of Reporting Trials (CONSORT) state-
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ment provides an excellent example of detailing
the quality of reporting [7]. It is speciﬁc to RCTs
but offers some excellent models for reporting in
general.
In accordance with the Belmont Report’s
“respect for persons,” members should respect the
rights of human subjects at all times [8]. Human
subjects issues arise in a variety of ways. Human
subjects may represent ID numbers in a paid claims
database, may be survey respondents, may be clin-
ical trial subjects, or may be patients whose medical
records are being reviewed. Regardless of the setting
in which the research is conducted or the nature of
the human subject deﬁnition, respect for the rights
of the human subjects must be paramount. In recent
times, stringent restrictions have been placed on
research involving human subjects and institutional
research review boards (IRBs) oversee much of the
research conducted. But even so, occasionally prob-
lems occur. For example, recently a major university
in the United States was involved in an incident
where a young woman died as a result of ingesting
a substance during a trial. That substance was
thought by the researchers to have been harmless,
yet it was found to have been a substance with a his-
tory of toxicity.
Privacy and conﬁdentiality must be respected and
guarded, and federal and state laws governing pro-
tection of medical information, such as HIPAA,
must be strictly observed. The information in data-
bases, medical records, and survey ﬁles must be
protected and individual patients or other human
subjects, such as prescribers, must not be identiﬁed. 
Members should respect the reputations and
rights of colleagues when engaged in collaborative
projects. From a design and research practices per-
spective, it is important to recognize that each indi-
vidual’s actions can positively or negatively affect
the reputation of his or her colleagues. It is thus
important to work closely with colleagues, obtain
agreement on the approach to the research design,
and obtain agreement on the data analysis and
interpretation of the results.
Members should maintain and protect the integ-
rity of the data used in their studies. Often data are
in the form of claims, either pharmacy or medical,
and these data are by deﬁnition not designed for
research. The researchers must assure that the data-
base is clean and that there is no patient duplica-
tion, that identiﬁers are unique, and that medical
and pharmacy claims are merged appropriately. In
other types of research, such as survey research or
medical records review, coding is very important.
And with regard to medical records review, the
records are rarely copied in their entirety so a priori
decisions need to be made as to exactly which data
to abstract from a chart.
Members should not draw conclusions beyond
those that their data would support. The data
should be used to test the hypotheses that were gen-
erated a priori and to support any subsequent anal-
yses. Nevertheless, the researchers in their design
and research practices must continue to adhere to
standards of practice and ethical precepts for their
disciplines and be certain to form only those con-
clusions that their data will support. For example, if
there is insufﬁcient power to conclude that there is
a signiﬁcant difference between two groups, this
should be reported as such.
Sponsorship
Sponsorship relates to initial decisions on whether
to conduct the research and the relationships
between the researchers and the sponsors. At all
times, the source of sponsorship for research should
be fully disclosed [1,6,9]. It allows the receiver of
the research, whether it is a reader or an entity that
is going to implement the research into their daily
practices or policies, to judge the level of conﬁdence
they might place in that research based on that
source. Members of ISPOR should strive to avoid
bias and the appearance of bias in conducting
research. The disclosure of the identity of the spon-
sor should serve to place sufﬁcient pressure on
researchers to be sure that their research and sub-
sequent publication is well balanced and as unbi-
ased as is possible. As a routine matter, most
journals require that authors disclose the source of
support for the research and they publish this infor-
mation as a footnote in most cases.
In reporting and conducting research, members
must be able to maintain their professional auton-
omy at all times [6]. In the long run, the information
reported might be better received with a higher level
of conﬁdence than if the researcher’s professional
autonomy were in question. Ultimately, the profes-
sional is responsible for the conduct of the research
and his or her reputation will certainly be affected
by perceptions that the research is biased or that
professional autonomy has been compromised.
Members should also avoid conﬂicts of interest
and the mere appearance of conﬂicts of interest [6].
In this area, members need to be most vigilant. It is
beyond the scope of this article to attempt to detail
every possible situation where a conﬂict of interest
might exist. Nevertheless, there are a few areas
where members would need to be concerned. These
include but are not limited to working for compet-
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ing clients in a product line that both clients pro-
duce without full knowledge on the part of both
clients that one is working for both, having substan-
tial ownership in a client’s company without divulg-
ing that information, or using conﬁdential data
from one client to perform work for another.
Publication and Dissemination
Research is often undertaken for a client where the
resulting product is a report to that client, which
then becomes the property of that client. This is
often the case in the private consulting arena. Often,
however, universities will refuse to sign a contract
where publication rights are restricted [10]. A more
common practice is to include a provision in the
contract that publication may be withheld for a
period of 3 to 6 months after which the investiga-
tors are free to publish. Usually this is designed to
address intellectual property issues but can be used
for virtually any reason at all.
ISPOR members should endeavor to publicly dis-
seminate all of their work and to publish it in peer-
reviewed journals when possible [11]. It has been
suggested that withholding publication is unethical.
For example, patients may enroll in clinical trials
for altruistic reasons and there may be a corre-
sponding obligation to them to see that the results
are brought to light [12]. ISPOR members should
have a philosophy of advancing knowledge in a par-
ticular area and should therefore publicly dissemi-
nate their work, holding it up to peer review.
Nevertheless, publication rights may be deﬁned in
advance, and members should respect contractual
rights, which limit their use of the data after the pri-
mary study is completed [10]. They should also
refrain from disseminating information, which was
agreed in advance and at the time the contract was
signed would remain proprietary.
Methods sections of articles should give thor-
ough, transparent attention to all measures taken
to minimize bias and should identify and defend all
departures from the a priori analysis plan. This
basically implies that the methods section of the
article should be thorough and detailed enough
so that the reader has a good understanding of
exactly how the research was conducted. For
example, sampling measures should be presented
in sufﬁcient detail to enable the reader to deter-
mine whether the sampling plan presents a particu-
lar bias. Analyses should be those that are best
suited to examining the data generated from the
study and testing the hypotheses that were pro-
posed in the study. Research often leads an investi-
gator down roads that he or she may not have
contemplated when drawing up the original
research plan. When this occurs it should be
reported truthfully, thus allowing the reader to
draw his/her own conclusions.
Members should not allow listing of an author
on any publication where that individual has not
performed substantial work, and members should
not exclude from listing as an author any individual
who has performed substantial work [10]. Author-
ship is often a difﬁcult problem within an organiza-
tion. The question often arises as to whether a
particular individual has performed work that is
substantial enough to merit listing as a coauthor.
One alternative, which can be considered by
researchers, is to acknowledge the contribution of
an individual in a footnote, when that individual
has not performed enough work to qualify as a
coauthor but has greatly assisted in the effort.
Members should utilize checklists, such as those
found in some major peer-reviewed journals, to
determine whether an individual should be included
as an author [13]. Although this does not address all
author-related issues, it is very helpful.
Finally, as a general rule, members should work
with editors of journals and other publications to
encourage an appropriate peer review process that
examines the quality of the methodologic rigor
rather than the institution for which the individual
works [1]. Nonetheless, any contributor should dis-
close relationships with a company or competitor of
any product discussed in the work so that the reader
can draw his or her own conclusions.
Role of  Professional Societies and Organizations
ISPOR is an organization representing members
from a variety of disciplines. As an organization,
ISPOR is not particularly interested in serving as
arbiter of complaints or as a licensure board but is
merely interested in putting forth a code of ethics
that its various members can subscribe to as part of
belonging to this organization. There are certain
roles and responsibilities that ISPOR, as a profes-
sional society, should undertake.
First, ISPOR should publicize this code of ethics
to both members and nonmembers. This could be
done through dissemination of information on the
ISPOR Web site as well as publication in hard copy
as a stand-alone document or a publication in a
peer-reviewed journal. Second, ISPOR should strive
for a balance in sponsorship of its conferences and
other activities thereby avoiding even the appear-
ance of bias or conﬂict of interest. Although, as with
other organizations, much of the funding for activ-
ities may come from one particular sector of the
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health-care industry, the organization should seek
to obtain support from other quarters. Because as a
practical matter, there is funding from commercial
interests, ISPOR should issue its own statement
of objectivity and autonomy from sponsors. Third,
ISPOR should continue to assure that its journal
publishes only articles that have gone through a rig-
orous peer review process. Fourth, ISPOR should
maintain a board of directors that is representative
of the various constituencies that the society serves.
Finally, ISPOR program planning and selection
committees should have membership representative
of the major constituencies.
The authors acknowledge the assistance of Ms. Ashley
Slagle, doctoral student in Pharmaceutical Health Services
Research at the University of Maryland.
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Appendix: ISPOR Code of Ethics 
for Researchers
Preamble
ISPOR, as an organization, expects itself and its
members to adhere to the highest ethical standards.
In doing so, ISPOR recognizes that its activities and
that of its members affect a number of constituen-
cies and these include but are not limited to:
• Patients who are ultimately going to experience
the greatest impact of the research.
• Decision makers and administrators who need
results that are both practical and useful.
• Practitioners who will be treating or not treat-
ing patients with therapies, medications, and
procedures made available or not made availa-
ble because of the research.
• Government groups who require the results of
research to set policy.
• The profession of outcomes researchers.
• Payers who must decide what is covered with-
out compromising the health of the patient.
• Colleagues, where relationships in conducting
research and its related activities are particu-
larly critical.
• Research employees and how they are
regarded, compensated, and treated by the
researchers for whom they work.
• Students who work for researchers, where
respect and lack of exploitation are important.
They are the future of the profession.
• Employers where the research affects their deci-
sions on providing health beneﬁts.
• Clients for whom the research is conducted and
the researchers’ relationships with them.
The following code of ethics for members of the
International Society for Pharmacoeconomics and
Outcomes Research includes ethical considerations
for ISPOR members on research practices, research
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sponsorship, research publication and dissemina-
tion, and relationships with others. This code of
ethics also includes ethical considerations for the
Society.
The code is something to which we believe all
ISPOR members should aspire. Nevertheless, we
recognize that members’ own organizations may
also have ethical codes that should be followed. We
also recognize that legal considerations may some-
times be important, for example, in relation to
employment law. Therefore, the code is advisory
rather than mandatory and ISPOR welcomes an
ongoing debate about ethical standards in the ﬁeld
of pharmacoeconomics and outcomes research.
Design and Research Practices
Members should maintain a current knowledge of
research practices.
• Members should adhere to the standards of
practice for their respective ﬁelds of research
and identify any ofﬁcial guidelines/standards
used.
• Members’ research designs should be deﬁned a
priori, reported transparently, defended relative
to alternatives, and planned to minimize all
types of bias.
• Members should respect the rights of research
subjects in designing and conducting studies.
• Members should respect the reputations and
rights of colleagues when engaged in collabora-
tive projects.
• Members should maintain and protect the
integrity of the data used in their studies.
• Members should not draw conclusions beyond
those, which their data would support.
Sponsorship
• Members should fully disclose the identity of
sponsors of their research.
• Members should strive to avoid bias and the
appearance of bias in conducting research.
• Members should avoid conﬂicts of interest and
the appearance of conﬂicts of interest. As a
point of reference, members should look to the
rules on disclosure of interest laid down by
major peer-reviewed journals.
• Members should maintain their professional
autonomy and objectivity in conducting and
reporting research.
Publication and Dissemination
• Members should endeavor to publicly dissemi-
nate all their work and to publish it in peer-
reviewed journals when possible.
• Members should discourage, where possible,
listing of an author on any publication where
the individual has not performed substantial
work. As a point of reference, members should
look to the checklists provided by major peer-
reviewed journals to assist them in deciding
inclusion of authors.
• Members should respect contractual rights
when they agree to perform work for hire and
should refrain from disseminating information,
which it was agreed, in advance and at the time
the contract was signed, would remain propri-
etary.
• Methods sections of articles should give thor-
ough, transparent attention to all measures
taken to minimize bias.
• Methods sections of articles should identify and
defend all departures from the a priori analysis
plan.
• Members should discourage the exclusion of an
author from any publication where the individ-
ual has performed substantial work.
• Members should work with editors of journals
and other publications to encourage an appro-
priate peer review process that examines the
quality of the methodologic rigor independ-
ently of the institution for which the individ-
ual works. Nonetheless, any contributor
should disclose relationships with a company
or competitor of any product discussed in the
work.
Relationships with Others
• Members should treat their research employees
with respect and should compensate them fairly
for their work.
• Members should protect and promote the inter-
ests of their employers, provide competent
work, adhering to these broader guidelines, and
protect proprietary information.
• Members should treat students with respect
and refrain from exploiting them under any cir-
cumstances.
• Members should provide competent, honest,
and objective work for clients, adhering at all
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times to relevant standards of conduct for con-
ducting and reporting research.
Role of  Professional Societies and Organizations
• ISPOR should publicize this code of ethics to
members and nonmembers.
• ISPOR should strive for a balance in sponsor-
ship of its conferences and other activities,
thereby avoiding the appearance of bias or con-
ﬂict of interest.
• Because, as a practical matter, most funding
will come from commercial interests, ISPOR
should issue its own statement of objectivity
and autonomy from sponsors.
• ISPOR should strive to assure that its journal,
Value in Health, publishes only articles that
have gone through a rigorous peer review
process.
• ISPOR should have a Board of Directors that is
representative of the various constituencies the
society serves.
• ISPOR program, planning, and selection com-
mittees should have membership representative
of all of its major constituencies.
